Latest Information Update: 16 Aug 2002
At a glance
- Originator Medinox
- Class Small molecules; Vascular disorder therapies
- Mechanism of Action Nitric oxide inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cerebrovascular disorders
Most Recent Events
- 19 Oct 1998 New profile
- 19 Oct 1998 Preclinical development for Cerebrovascular disorders in USA (Unknown route)